IO Primer: Immune-Related Adverse Events: This brief knowledge-building module reviews the mechanisms of immune-related adverse events (irAEs) and provides practical strategies for managing irAEs in clinical practice.
The EIOCC IO Toxicity Tool integrates guideline recommendations on the management of immune-related adverse events (irAEs) from the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN) and Society for Immunotherapy of Cancer (SITC).
Jacobson A, Macfarlane CL, Pozniak E (2020) Feasibility of Integrating a Mobile Decision-Support App into a Multicomponent CME Initiative: Developing Clinician Competence at the Point of Care. JECME. 9:1, 1834762, DOI: 10.1080/21614083.2020.1834762
The field of immuno-oncology (IO) focuses on using novel immunotherapies to enhance the body’s ability to fight cancer. Advances in IO are changing the standards of cancer care at an unprecedented pace, creating a challenge for oncologists and nurses to stay on top of the latest treatment developments. The European Immuno-Oncology Clinic Companion (EIOCC) is a needs-based, multicomponent educational initiative designed to support and facilitate increased knowledge, competence, and performance among oncology professionals involved in the use of IO agents.
The brief knowledge-building modules review essential topics in immuno-oncology (IO), including the immune system and cancer therapy, mechanisms of action of immune checkpoint inhibitors, assessing response to IO therapy and immune-related adverse events.
The case challenges explore the role of checkpoint inhibitor therapy in the management of cancer, including advanced renal cancer, advanced bladder cancer, advanced melanoma and Hodgkin lymphoma.
The webcast modules, recorded at the ECOS 2019 meeting, feature cardio-oncology experts holding multidisciplinary sessions with interactive discussion and case reviews.
Test and build your knowledge of core concepts in immuno-oncology (IO) therapy with challenging patient cases in cancer, including bladder, lung, colorectal and kidney cancer, as well as lymphoma and melanoma.
Tweets by EuroImmunoOnc
What is the future of IO therapy in renal and bladder cancers? Listen as EIOCC faculty Maria Carmen Mir, MD, PhD, and Mario W. Kramer, MD, discuss the emerging role of immune checkpoint inhibitors in patient care.
The University of Manchester Innovation Centre (UMIC)